Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Lin HM, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK, Kench JG, Stricker PD, Haynes AM, Centenera MM, Butler LM, Shreeve SM, Horvath LG, Daly RJ.

Prostate. 2018 Mar;78(4):308-317. doi: 10.1002/pros.23476. Epub 2018 Jan 5.

PMID:
29314097
2.

Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.

Lee BY, Hochgräfe F, Lin HM, Castillo L, Wu J, Raftery MJ, Martin Shreeve S, Horvath LG, Daly RJ.

Mol Cancer Ther. 2014 Jan;13(1):190-201. doi: 10.1158/1535-7163.MCT-13-0225-T. Epub 2013 Nov 5.

3.

Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.

Miller DR, Tzeng CC, Farmer T, Keller ET, Caplan S, Chen YS, Chen YL, Lin MF.

Cancer Lett. 2018 Nov 1;436:96-108. doi: 10.1016/j.canlet.2018.07.039. Epub 2018 Aug 3.

PMID:
30077739
4.

Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.

Nelius T, Martinez-Marin D, Hirsch J, Miller B, Rinard K, Lopez J, de Riese W, Filleur S.

Cell Death Dis. 2014 May 8;5:e1210. doi: 10.1038/cddis.2014.180.

5.

Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.

Wu F, Lin Y, Cui P, Li H, Zhang L, Sun Z, Huang S, Li S, Huang S, Zhao Q, Liu Q.

Cancer Chemother Pharmacol. 2018 Jun;81(6):999-1006. doi: 10.1007/s00280-018-3578-8. Epub 2018 Mar 31.

PMID:
29605876
6.

Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.

Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma S.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):349-357. doi: 10.1038/pcan.2016.21. Epub 2016 Jun 28.

7.

Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.

J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101. Epub 2013 Aug 15.

PMID:
23954373
8.

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.

Toren P, Kim S, Johnson F, Zoubeidi A.

PLoS One. 2016 Apr 5;11(4):e0152861. doi: 10.1371/journal.pone.0152861. eCollection 2016.

9.

Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.

Park H, Kim Y, Sul JW, Jeong IG, Yi HJ, Ahn JB, Kang JS, Yun J, Hwang JJ, Kim CS.

Prostate. 2015 Nov;75(15):1747-59. doi: 10.1002/pros.23057. Epub 2015 Aug 7.

PMID:
26250606
10.

Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.

Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW, Sweeney CJ.

Proc Natl Acad Sci U S A. 2016 May 31;113(22):6259-64. doi: 10.1073/pnas.1600420113. Epub 2016 May 16.

11.

Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.

François RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M.

J Natl Cancer Inst. 2015 May 12;107(8). pii: djv123. doi: 10.1093/jnci/djv123. Print 2015 Aug.

12.

NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.

Chen Z, Jiang Q, Zhu P, Chen Y, Xie X, Du Z, Jiang L, Tang W.

Prostate. 2019 Jan;79(1):44-53. doi: 10.1002/pros.23709. Epub 2018 Sep 3.

PMID:
30178500
13.

The role of testicular nuclear receptor 4 in chemo-resistance of docetaxel in castration-resistant prostate cancer.

Chen B, Yu S, Ding X, Jing C, Xia L, Wang M, Matro E, Rehman F, Niu Y, Li G, Chang C.

Cancer Gene Ther. 2014 Oct;21(10):411-5. doi: 10.1038/cgt.2014.41. Epub 2014 Aug 8.

PMID:
25104727
14.

Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.

Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, Zand B, Liu T, Huang J, Jennings NB, Rupaimoole R, Taylor M, Pradeep S, Wu SY, Lu C, Wen Y, Huang J, Liu J, Sood AK.

J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. doi: 10.1093/jnci/djt210. Epub 2013 Sep 23.

15.

Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.

Park SE, Kim HG, Kim DE, Jung YJ, Kim Y, Jeong SY, Choi EK, Hwang JJ, Kim CS.

Invest New Drugs. 2018 Apr;36(2):195-205. doi: 10.1007/s10637-017-0529-x. Epub 2017 Nov 7.

PMID:
29110173
16.

Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.

Cardillo I, Spugnini EP, Galluzzo P, Contestabile M, Dell'Anna ML, Picardo M, Crispi S, Calogero RA, Piccolo MT, Arigoni M, Cantarella D, Boccellino M, Quagliuolo L, Ferretti G, Carlini P, Felici A, Boccardo F, Cognetti F, Baldi A.

Future Oncol. 2013 Sep;9(9):1375-88. doi: 10.2217/fon.13.99.

PMID:
23980684
17.

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.

Clin Cancer Res. 2014 Jun 15;20(12):3198-3210. doi: 10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16. Erratum in: Clin Cancer Res. 2017 Jan 1;23 (1):323.

18.

Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.

Jarvis C, Nelius T, Martinez-Marin D, Sennoune SR, Filleur S.

Prostate. 2018 Sep;78(12):905-914. doi: 10.1002/pros.23647. Epub 2018 May 10.

PMID:
29749077
19.

Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.

Park HS, Hong SK, Oh MM, Yoon CY, Jeong SJ, Byun SS, Cheon J, Lee SE, Moon du G.

Anticancer Res. 2014 Jul;34(7):3457-68.

PMID:
24982354
20.

The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.

Yu L, Wu X, Chen M, Huang H, He Y, Wang H, Li D, Du Z, Zhang K, Goodin S, Zheng X.

Int J Med Sci. 2017 Apr 7;14(4):356-366. doi: 10.7150/ijms.18382. eCollection 2017.

Supplemental Content

Support Center